TLDR Semaglutide helps obese PCOS patients lose weight and improve health.
This study evaluated the effects of semaglutide on 27 obese PCOS patients unresponsive to lifestyle changes. After three months of weekly 0.5 mg subcutaneous semaglutide treatment, patients experienced an average weight loss of 7.6 kg and a BMI reduction of 3.1, with 80% achieving at least a 5% weight reduction. The treatment also improved insulin resistance and normalized fasting blood glucose in 80% of patients with impaired fasting glucose. For those who continued treatment for six months, the average weight loss increased to 11.5 kg, and BMI decreased from 34.4 to 29.4, with 80% of responsive patients experiencing normalized menstrual cycles. The study concluded that low-dose semaglutide effectively reduces body weight and improves metabolic and reproductive outcomes in obese PCOS patients with minimal side effects.
49 citations
,
February 2019 in “The Journal of Clinical Endocrinology and Metabolism” Use "female pattern hair loss" term, assess androgen excess, treat with minoxidil and other medications if needed.
117 citations
,
May 2017 in “Human Reproduction Update” The update highlights that non-classic congenital adrenal hyperplasia is common in women with excess male hormones, requires specific hormone tests for diagnosis, and has various treatment options depending on age and symptoms.
883 citations
,
August 2016 in “Nature Reviews Disease Primers” Polycystic Ovary Syndrome (PCOS) is a common condition in women that can cause metabolic, reproductive, and psychological issues, and requires lifestyle changes and medication for management.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
September 2025 in “Wound Repair and Regeneration” GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
August 2024 in “Nutrition Bulletin” GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
